Title : Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.

Pub. Date : 2016 Jan 28

PMID : 26317591






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The work described herein culminated in the 2014 FDA approval of suvorexant as a first-in-class dual orexin receptor antagonist for the treatment of insomnia. suvorexant hypocretin neuropeptide precursor Homo sapiens